Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states by Machado, PM et al.
Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for 
disease activity states 
Pedro M. Machado,1 Robert Landewé,2 Désirée van der Heijde,3 for the Assessment of 
SpondyloArthritis international Society (ASAS) 
1Centre for Rheumatology & MRC Centre for Neuromuscular Diseases, University College London, 
London, UK; 2Academic Medical Center, Amsterdam & Atrium Medical Center Heerlen, 
Netherlands; 3Department of Rheumatology, Leiden University Medical Center, Leiden, the 
Netherlands;  
 
Correspondence to:  
Pedro M Machado 
University College London 
1st Floor, Russell Square House 
10-12 Russell Square 
London WC1B 5EH 
Phone: +442031087515 
Email: p.machado@ucl.ac.uk 
 
 
The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a measure of axial spondyloarthritis 
(axSpA) disease activity with validated cut-offs endorsed by the Assessment of Spondyloarthritis 
international Society (ASAS) and Outcome Measures in Rheumatology (OMERACT).1,2 In the 2016 
update of the ASAS-EULAR management recommendations for axSpA it is recommended that 
biological disease-modifying antirheumatic drugs (bDMARDs) should be considered in patients 
with persistently high disease activity despite conventional treatments, and that the preferred 
measure to define active disease should be the ASDAS (ASDAS of at least 2.1, i.e. high disease 
activity).3 The 2017 update of treat-to-target recommendations in axial and peripheral SpA, 
recommends that the treatment target should be inactive disease/clinical remission and that 
low/minimal disease activity may be an alternative treatment target. The same recommendations 
state that the preferred measure to define the target in axSpA is the ASDAS.4 
ASDAS cut-offs for disease activity states are 1.3, separating “inactive disease” from “moderate 
disease activity”, 2.1, separating “moderate disease activity” from “high disease activity”, and 3.5, 
separating “high disease activity” from “very high disease activity”. While inactive disease equates 
to a remission-like state, there is no low/minimal disease equivalent in the above nomenclature of 
ASDAS cut-offs. At the 2018 ASAS annual meeting in Lisbon, Portugal, ASAS members discussed 
the proposal of changing the nomenclature of ASDAS cut-offs in order to fill this gap. 
Arguments to change the designation of “moderate disease activity” to “low disease activity” were 
presented. The compelling argument is the fact that the majority of patients in this ASDAS 
category have indeed mild disease activity, an observation that is in line with the external 
constructs that were used to derive the ASDAS cut-off of 2.1: patient and physician global 
assessments <3, using the 90% specificity criterion to determine the optimal cut-off.1,5 
Furthermore, recent publications have shown that the majority of patients with ASDAS values in 
the “moderate disease activity” category consider themselves as being in a patient-acceptable 
symptom state (PASS), which can be defined as the maximum level of symptoms with which 
patients consider themselves to be well. Godfrin-Valnet et al6 found that agreement between 
ASDAS-C-reactive protein (CRP) and ASDAS-erythrocyte sedimentation rate (ESR) was good and 
that values of ≤2.3 for each were associated with the PASS. A previous study by Rodriguez-Lozano 
et al7 suggested cut-off values between 2.5 and 3.0 for ASDAS-CRP and cut-off values between 2.8 
and 3.5 for ASDAS-ESR (PASS as external construct), depending on the method used to determine 
the cut-off value. A more recent study by Sellas et al8 suggested that the ASDAS cut-off of 2.04 was 
associated with patient-PASS while the ASDAS cut-off of 2.44 was associated with physician-PASS.  
Following an open discussion among ASAS members about the topic, the proposed nomenclature 
change from ASDAS “moderate disease activity” to ASDAS “low disease activity” was voted and 
approved by ASAS members (Figure 1). Other possibilities that were considered but rejected by 
ASAS members were the use of the wording “low/moderate disease activity”, “mild disease 
activity” and “moderate/high disease activity” (the later proposed to replace “high disease 
activity” state). 
In conclusion, the nomenclature of ASDAS disease activity states was updated by ASAS. The 
“moderate disease activity” state is replaced by “low disease activity” state, better reflecting the 
opinion of patients and physicians about what ASDAS values ≥1.3 and <2.1 represent. This change 
will improve the interpretability of ASDAS scores and will facilitate the implementation of treat-to-
target strategies in axSpA. 
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Figure 1. 2018 update of the nomenclature for ASDAS disease activity states. ASDAS, Ankylosing 
Spondylitis Disease Activity Score. 
 
 
